TARDBP Protein (TDP-43)

Pathway Diagram

flowchart TD
    TARDBP["TARDBP"]
    style TARDBP fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    TDP_43["TDP-43"]
    TARDBP -->|"associated with"| TDP_43
    DEMENTIA["DEMENTIA"]
    TARDBP -->|"associated with"| DEMENTIA
    FRONTOTEMPORAL_DEMENTIA["FRONTOTEMPORAL DEMENTIA"]
    TARDBP -->|"associated with"| FRONTOTEMPORAL_DEMENTIA
    Amyotrophic_Lateral_Sclerosis["Amyotrophic Lateral Sclerosis"]
    TARDBP -->|"risk factor for"| Amyotrophic_Lateral_Sclerosis
    NEURON["NEURON"]
    TARDBP -->|"associated with"| NEURON
    Als["Als"]
    TARDBP -->|"associated with"| Als
    RPTOR["RPTOR"]
    TARDBP -->|"regulates"| RPTOR
    FTD["FTD"]
    TARDBP -->|"associated with"| FTD
    FUS["FUS"]
    FUS -->|"associated with"| TARDBP
    ALS["ALS"]
    ALS -->|"associated with"| TARDBP
    NEURODEGENERATION["NEURODEGENERATION"]
    NEURODEGENERATION -->|"associated with"| TARDBP
    SOD1["SOD1"]
    SOD1 -->|"associated with"| TARDBP
    h_7e846ceb["h-7e846ceb"]
    h_7e846ceb -->|"therapeutic target"| TARDBP
    h_4fabd9ce["h-4fabd9ce"]
    h_4fabd9ce -->|"therapeutic target"| TARDBP
    h_eea667a9["h-eea667a9"]
    h_eea667a9 -->|"therapeutic target"| TARDBP
    h_7e846ceb -->|"targets gene"| TARDBP
    style TDP_43 fill:#4a1a6b,stroke:#ce93d8,color:#e0e0e0
    style DEMENTIA fill:#ef5350,stroke:#ef5350,color:#e0e0e0
    style FRONTOTEMPORAL_DEMENTIA fill:#ef5350,stroke:#ef5350,color:#e0e0e0
    style Amyotrophic_Lateral_Sclerosis fill:#ef5350,stroke:#ef5350,color:#e0e0e0
    style NEURON fill:#006494,stroke:#888,color:#e0e0e0
    style Als fill:#ef5350,stroke:#ef5350,color:#e0e0e0
    style RPTOR fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style FTD fill:#ef5350,stroke:#ef5350,color:#e0e0e0
    style FUS fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style ALS fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style NEURODEGENERATION fill:#006494,stroke:#888,color:#e0e0e0
    style SOD1 fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style h_7e846ceb fill:#006494,stroke:#888,color:#e0e0e0
    style h_4fabd9ce fill:#006494,stroke:#888,color:#e0e0e0
    style h_eea667a9 fill:#006494,stroke:#888,color:#e0e0e0

Overview

TARDBP encodes TDP-43 (TAR DNA-binding protein of 43 kDa), a DNA/RNA-binding protein that is a major pathological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Abnormal aggregation of TDP-43 in cytoplasmic inclusions is a defining feature of approximately 95% of ALS cases and 50% of FTD cases. ^{1TDP-43 in neurodegeneration: from mechanisms to therapy, Nat Rev Neurol (2023)2023 · PMID 37294826Open reference}

TDP-43 is a ubiquitously expressed nuclear protein with essential functions in RNA processing. The protein localizes predominantly to the nucleus in healthy cells but redistributes to the cytoplasm in disease states, forming characteristic inclusions that define a new class of proteinopathies. This pathology is found not only in ALS and FTD but also in many other neurodegenerative diseases, making TDP-43 a central player in neurodegeneration research. ^{2Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS, Science (2006)2006 · PMID 17023659Open reference 3TDP-43 is a component of ubiquitin-positive tau-negative inclusions, Biochem Biophys Res Commun (2006)2006 · PMID 17027740Open reference}

Molecular Biology and Structure

Protein Architecture

TDP-43 is a 414-amino acid protein with multiple functional domains:

N-Terminal Domain (1-76 aa):

• Contains the nuclear localization signal (NLS)

• Required for nuclear import

• Mediates protein-protein interactions

• Enables DNA binding

RNA Recognition Motif (RRM) Domain (106-262 aa):

• Highly conserved RNA-binding domain

• Recognizes (UG)n repeat sequences in RNA

• Binds both DNA and RNA with similar affinity

• Essential for most TDP-43 functions

• Contains two RNP motifs (RNP1 and RNP2)

Glycine-Rich Domain (274-414 aa):

• C-terminal region with low complexity

• Prone to aggregation

• Contains most disease-causing mutations (>50 known)

• Mediates interactions with other RNA-binding proteins

• Critical for protein solubility

Key Structural Features:

• The RRM domain has a classic β-α-β-fold RNA-binding motif

• The C-terminal domain is intrinsically disordered

• Post-translational modifications (phosphorylation, ubiquitination) affect function

• Forms multimers through C-terminal interactions

^{4TDP-43 functions in RNA metabolism and disease, Nat Rev Neurosci (2024)2024 · PMID 38452167Open reference}

Normal RNA Processing Functions

In the normal state, TDP-43 participates in numerous RNA processing functions:

1. Alternative Splicing:

• Regulates inclusion/exclusion of exons

• Influences splice site selection

• Important for neuronal-specific splicing patterns

• Targets include CFTR, tau, and neuronal transcripts

2. mRNA Stability:

• Binds to 3’ UTR regions

• Affects mRNA decay rates

• Regulates transcript stability

• Involved in RNA quality control

3. RNA Transport:

• Participates in mRNA trafficking to synapses

• Localizes to dendritic compartments

• Supports activity-dependent translation

• Important for synaptic plasticity

4. Transcription Regulation:

• Can act as transcriptional co-activator/repressor

• Modulates gene expression

• Interacts with transcriptional machinery

5. miRNA Processing:

• Associates with Drosha complex

• Affects miRNA biogenesis

• Links to post-transcriptional regulation

6. Stress Response:

• Transiently localizes to stress granules under cellular stress

• Helps regulate stress-response mRNAs

• Part of the cellular stress response machinery

^{5TDP-43 and FUS: a nuclear affair, Trends Neurosci (2012)2012 · PMID 22119501Open reference}

Role in Disease

Amyotrophic Lateral Sclerosis (ALS)

ALS is a progressive neurodegenerative disease affecting upper and lower motor neurons. TDP-43 pathology is present in ~95% of ALS cases, making it the most common protein aggregate in this disease.

Pathology:

• TDP-43 is the major constituent of cytoplasmic inclusions in motor neurons

• Loss of nuclear TDP-43 and cytoplasmic accumulation is characteristic

• Inclusions are ubiquitin-positive but tau-negative

• Pathological phosphorylation at serine 409/410

• Fragmentation of full-length TDP-43 into ~25-35 kDa fragments

Genetics:

• Over 50 mutations in TARDBP cause familial and sporadic ALS

• Mutations primarily in the C-terminal glycine-rich domain

• Account for ~5% of familial ALS cases

• Provide direct evidence that TDP-43 dysfunction causes disease

• Include missense (e.g., A315T, G348C, Q331K) and truncation mutations

Pathogenic Mechanisms: The precise mechanisms by which TDP-43 mutations cause disease remain under investigation:

1. Loss of nuclear function: Mutations may impair RNA processing, leading to altered splicing and expression of essential neuronal genes

2. Gain of toxic cytoplasmic function: Cytoplasmic aggregates may sequester essential proteins and RNAs

3. Stress granule dysregulation: Aberrant stress granule dynamics contribute to pathology

4. Mitochondrial dysfunction: TDP-43 affects mitochondrial gene expression

5. Excitotoxicity: Altered glutamate transporter expression may contribute

^{6TARDBP mutations in sporadic and familial ALS, Proc Natl Acad Sci USA (2008)2008 · PMID 18626014Open reference 7TARDBP mutations in French Canadian familial ALS, Nat Genet (2010)2010 · PMID 20453856Open reference 8TDP-43 mutations in familial and sporadic ALS, Science (2011)2011 · PMID 18819963Open reference 9ALS mutations in TDP-43 and its nuclear function, Nat Rev Neurol (2018)2018 · PMID 30131570Open reference}

Frontotemporal Dementia (FTD)

FTD is a spectrum of neurodegenerative disorders characterized by progressive behavioral and language deficits. TDP-43 pathology is found in approximately 50% of FTD cases.

Pathology:

• TDP-43 inclusions in neurons and glia of frontal and temporal cortices

• Characteristic “type B” FTLD-TDP pathology

• Neuronal loss and gliosis in affected regions

• Subtypes based on distribution and pattern of inclusions

Spectrum Disease:

• ALS-FTD overlap syndrome with TDP-43 pathology

• Many patients show features of both conditions

• Shared genetic and pathological mechanisms

• Common in cases with C9orf72 expansions

Clinical Presentations:

• Behavioral variant FTD (bvFTD)

• Primary progressive aphasia (PPA)

• Semantic variant PPA

• Progressive nonfluent aphasia

^{10TDP-43 pathology in ALS/FTD: new insights, Acta Neuropathol (2022)2022 · PMID 35698765Open reference 2Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS, Science (2006)2006 · PMID 17023659Open reference}0

Alzheimer’s Disease Co-Pathology

TDP-43 pathology is commonly observed in Alzheimer’s disease:

Prevalence:

• TDP-43 pathology observed in ~30-50% of AD cases

• Often in limbic regions (hippocampus, amygdala)

• More common with increasing AD severity

• Often accompanies amyloid and tau pathology

Clinical Impact:

• May contribute to cognitive decline beyond AD pathology

• Associated with more rapid progression

• Often in limbic regions

• Can be a primary or secondary pathology

Relationship to AD:

• Specific TDP-43 strains may differ from ALS/FTD

• May interact with tau pathology

• Role in disease progression actively studied

^{2Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS, Science (2006)2006 · PMID 17023659Open reference}1

Other Neurodegenerative Diseases

TDP-43 pathology is increasingly recognized in other conditions:

Parkinson’s Disease:

• TDP-43 inclusions in some cases

• Often in older patients

• May contribute to disease progression

• Can be primary or secondary

Dementia with Lewy Bodies (DLB):

• TDP-43 pathology in ~15-20% of cases

• Often coexists with Lewy bodies

• May affect clinical phenotype

Huntington’s Disease:

• TDP-43 co-pathology in some patients

• May affect disease expression

• Interaction with mutant huntingtin

Other Conditions:

• Chronic traumatic encephalopathy

• Some epilepsy cases

• Inclusion body myositis

^{2Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS, Science (2006)2006 · PMID 17023659Open reference}2

Mechanisms of Pathogenesis

Nuclear Loss vs Cytoplasmic Gain

The fundamental question in TDP-43 proteinopathy is whether disease results from loss of nuclear function, gain of toxic cytoplasmic function, or both.

Loss of Nuclear Function Evidence:

• Reduced nuclear TDP-43 in patient tissue

• Mutations impair RNA binding

• Altered splicing of target transcripts

• Nuclear clearance mechanisms may contribute

Cytoplasmic Gain of Function Evidence:

• Cytoplasmic inclusions are pathological hallmark

• Overexpression of wild-type TDP-43 causes toxicity

• Cytoplasmic TDP-43 disrupts mitochondrial function

• Sequestration of essential RNAs in aggregates

The current consensus suggests both mechanisms contribute to disease, and therapeutic approaches may need to address both.

^{2Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS, Science (2006)2006 · PMID 17023659Open reference}3 ^{2Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS, Science (2006)2006 · PMID 17023659Open reference}4

Aggregation Mechanism

TDP-43 aggregation is central to disease pathogenesis:

Aggregation Process:

• C-terminal domain drives aggregation

• Low complexity region enables liquid-liquid phase separation

• Pathological phosphorylation at S409/410 promotes aggregation

• Truncation fragments seed aggregation

• Prion-like spread between cells

Cell-to-Cell Transmission:

• TDP-43 aggregates can transfer between cells

• May propagate pathology in a prion-like manner

• Observed in cell culture and animal models

• Could explain spread along neural networks

Oligomer Formation:

• Soluble oligomers may be toxic species

• Multiple oligomeric species identified

• Different from mature inclusions

• Therapeutic target

^{2Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS, Science (2006)2006 · PMID 17023659Open reference}5 ^{2Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS, Science (2006)2006 · PMID 17023659Open reference}6

Stress Granules and TDP-43

Stress granules are cytoplasmic RNA-protein aggregates that form during cellular stress. TDP-43 transiently localizes to stress granules, and this process is dysregulated in disease.

Normal Stress Granule Function:

• Form under stress to protect mRNAs

• Contain translationally stalled mRNPs

• Disassemble when stress resolves

Dysregulation in Disease:

• TDP-43 forms persistent stress granule-like inclusions

• Mutations alter stress granule dynamics

• Stress granules may seed pathological aggregates

• Chronic stress may drive pathology

Therapeutic Implications:

• Modulating stress granule dynamics may help

• Preventing TDP-43 recruitment to stress granules

^{2Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS, Science (2006)2006 · PMID 17023659Open reference}7

Therapeutic Targeting

Antisense Oligonucleotides (ASOs)

ASOs targeting TARDBP mRNA represent the most advanced therapeutic approach:

Mechanism:

• ASOs bind to TARDBP mRNA

• RNase H-mediated degradation reduces TDP-43 protein

• Can be delivered to CNS via intrathecal injection

• Reduce pathological TDP-43

Clinical Status:

• Multiple ASO programs in clinical trials

• Early-phase trials in ALS patients

• Some success in reducing CSF TDP-43

• Challenges: delivery, timing, patient selection

Approaches:

• Gene knockdown ASOs

• Allele-selective ASOs for specific mutations

• Combination approaches

^{2Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS, Science (2006)2006 · PMID 17023659Open reference}8 ^{2Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS, Science (2006)2006 · PMID 17023659Open reference}9

Small Molecule Inhibitors

Small molecules targeting TDP-43 aggregation are under development:

Target Areas:

• Prevent aggregation of TDP-43

• Promote clearance of aggregates

• Modulate post-translational modifications

Challenges:

• Target engagement in CNS

• Compound properties for brain penetration

• Disease stage for intervention

Current Candidates:

• Aggregation inhibitors in screening

• Compounds targeting phosphorylation

• Molecules promoting autophagy

Gene Therapy Approaches

Viral vector delivery of corrected TARDBP or modulators:

Approaches:

• AAV-delivered shRNA/siRNA for knockdown

• Gene delivery of wild-type TDP-43

• CRISPR-based approaches

• RNA-binding protein modulators

Challenges:

• Delivery to appropriate CNS regions

• Achieving sufficient knock-down

• Avoiding off-target effects

• Safety considerations

^{3TDP-43 is a component of ubiquitin-positive tau-negative inclusions, Biochem Biophys Res Commun (2006)2006 · PMID 17027740Open reference}0

Symptomatic and Disease-Modifying Approaches

Symptomatic:

• Standard ALS/FTD management

• Riluzole, edaravone in ALS

• Supportive care

• Symptom-targeted therapies

Disease-Modifying:

• Modulating TDP-43 pathology

• Targeting upstream mechanisms

• Combination approaches

Protein Interactions

Research Directions

Emerging Areas

1. Structural biology: Atomic resolution of TDP-43 aggregates

2. Strains: Different TDP-43 strains in different diseases

3. Biomarkers: CSF and imaging biomarkers

4. iPSC models: Patient-derived neurons

5. Gene therapy: Viral delivery systems

Biomarker Development

• TDP-43 levels in CSF

• PET ligands for TDP-43 aggregates

• Genetic testing for mutations

• Fluid biomarkers for disease progression

Animal Models

Transgenic Models

• TARDBP transgenic mice: Overexpress wild-type or mutant TDP-43

• Knockin models: Express human mutations in endogenous gene

• Conditional models: Inducible expression systems

• Optic nerve models: Visual system studies

Phenotypes

• Motor neuron degeneration

• Behavioral deficits

• Gliosis

• Protein aggregation

• Shorter lifespan

^{3TDP-43 is a component of ubiquitin-positive tau-negative inclusions, Biochem Biophys Res Commun (2006)2006 · PMID 17027740Open reference}1

See Also

• TARDBP Gene — Gene page

• ALS — Associated disease

• FTD — Associated disease

• TDP-43 Proteinopathy — Mechanism

• Protein Aggregation — Pathological mechanism

• RNA Metabolism — Cellular process

• Stress Granules — Disease mechanism

External Links

• UniProt: Q13148 - Protein database

• PubMed: TARDBP - Literature search

• PDB: 2N4P - Protein structure

• GeneCards: TARDBP

• HGNC: TARDBP

Structure

AlphaFold DB provides a full-length predicted structure for TARDBP (UniProt Q13148, model v6) with mean pLDDT 65.19. View the model at AlphaFold DB or download the PDB file.

Domain and region confidence from per-residue pLDDT:

• Residues 82-98 (Nuclear localization signal): mean pLDDT 45.1 (very low).

• Residues 104-200 (RRM 1): mean pLDDT 80.4 (confident).

• Residues 191-262 (RRM 2): mean pLDDT 80.5 (confident).

• Residues 216-414 (Interaction with UBQLN2): mean pLDDT 51.8 (low).

• Residues 239-250 (Nuclear export signal): mean pLDDT 77.9 (confident).

• Residues 261-303 (Disordered): mean pLDDT 43.1 (very low).

• Residues 341-373 (Disordered): mean pLDDT 41.0 (very low).

Overall confidence distribution: 4 residues (1%) very high, 213 residues (51%) confident, 41 residues (10%) low, 156 residues (38%) very low. Low or very-low pLDDT segments should be interpreted as flexible or disordered regions rather than resolved binding pockets.

UniProt function annotation: RNA-binding protein that is involved in various steps of RNA biogenesis and processing (PubMed:23519609). Preferentially binds, via its two RNA recognition motifs RRM1 and RRM2, to GU-repeats on RNA molecules predominantly localized within long introns and in the 3’UTR of mRNAs (PubMed:23519609, PubMed:24240615, PubMed:24464995). In turn, regulates the. Subcellular localization: Nucleus, Cytoplasm, Cytoplasm, Stress granule, Mitochondrion. Curated disease associations include: Amyotrophic lateral sclerosis 10.